International Journal of Health Sciences and Research
Vol.12; Issue: 3; March 2022
Website: www.ijhsr.org
Review Article *ISSN: 2249-9571*

Current Incorporation and Impact of Computational Biology in Alzheimer's Disease

Sadaf Naaz[1,2], Sweety Guria Rani[1,2], Purbasha Pati[1,2], Kumari Surekha Mahto[1,3], Shekhar Marandi[1,3], Priyangulta Beck[1,3], Neha Kumari[1,4], Pooja Kumari[1,4], Rupa Verma[1,3], Nawed Anjum[4], Mukesh Nitin[1]

[1]Department of Tech. Biosciences, Digianalix, South Samaj Street, Tharpakhna, Ranchi-834001, Jharkhand, India.
[2]Department of Biotechnology, Ranchi Women's College, Circular Rd. Nagra Toli, Ranchi- 834001, Jharkhand, India.
[3]Department of Biotechnology, Ranchi University, Ranchi, Jharkhand, India.
[4]Department of Biotechnology, Birla Institute of Technology, Mesra-835215, Jharkhand, India.

Corresponding Author: Mukesh Nitin

DOI: https://doi.org/10.52403/ijhsr.20220345

ABSTRACT

Alzheimer's disease (Senile Dementia) is a neurological disorder that slowly destroys memory and disseminates thinking skills. Approximately 5 million people are already affected by this disease in the United States. It shows that, up to 2060, the number of patients will increase threefold. With advances in computational biology and next-generation sequence, multiple experimentation are undergoing in exploring the novel and functional role of genes during Alzheimer's disease. Recently development of next-generation sequence machine and bioinformatics has started to investigate the placement of genetics within the pathogenesis of Alzheimer's disease, collectively with the consequences of genome-wide association studies (GWAS) that have implicated a number of the unconventional genes as risk factors. In this review we discuss the current scenario and advances in computational biology towards Alzheimer's disease research.

Keywords: Alzheimer's disease, next-generation sequence, GWAS, computational modelling, bioinformatics.

INTRODUCTION

Alzheimer's disease (AD) is prominently visible within the developing age elders. This disorder is a progressive, incurable, deadly commonly occurring in humans above age bar 40. It is a neurological sickness in which mind cells die.[1] Memory loss, confusion, incapacity to examine new matters, aggression, anger, depression, and disorganization are symptoms of Alzheimer's disease.[2] Recently the studies on the function of vitamins performed a vital contribution to lowering the danger of Alzheimer's disease.[3] Genetic, environmental and nutritional elements impact the development of Alzheimer's disorder.

AD is recognized by degeneration of neurons and disturbances in neuronal synapses inside cortical and subcortical areas; till now proven through neurobiological data.[4] Amyloid precursor protein (APPs) is a trans-membrane protein that neurons increase and post-damage restore, as proven through proteomic studies.[5] It effects within the manufacturing of Aβ, then dumped into the extracellular area following vesicle recycling or degraded in lysosomes, then it affects neurodegeneration in Alzheimer's disease as shown in Fig. 1.



Fig. 1. Treatment of Alzheimer's disease.

The pathobiology of Alzheimer's disease is complex with genetic and epigenetic events which might be involved inside the disease pathogenesis.[6] While the hallmarks of the illness include the buildup of amyloid plaques and tangles of neurofibrils inside the brain.,[7] how the ones are associated with Alzheimer's disease development and what are the vital underlying mechanisms of Alzheimer's disease is uncertain.

Many genetic variations associated with complex tendencies and pathological conditions, collectively with neurodegenerative diseases, had been discovered by Genome-wide association studies (GWAS).[8, 9] To become mindful of biomarkers and molecular pathways of the mind, human genomic and transcriptomic information can be essential.

Genomics and genetics strategies helped in revealing the mechanisms underlying AD. Genome-wide affiliation studies (GWAS) and meta-analyses have diagnosed 23 statistically sizable Alzheimer sickness-related genes.[10] Overall, 39 AD risk genes have been identified so far, which include APOE, APP, TRIP4, ABCA7, and SORL1.[11,12] These genes highlight the importance of several pathways involved in AD, in conjunction with immune response, inflammation, cell migration, lipid delivery, endocytosis, hippocampal synaptic function and different cell regulatory processes, collectively with the characteristic of tau and amyloid protein. Previous research has consequently used system learning to construct multi-biomarker fashions for scientific prognosis and prediction of Alzheimer sickness primarily based on the size of RNA, protein, and lipid degrees in blood samples.[13,14] Support Vector Machine(SVM) and random forest(RF) fashions have proved predictive in distinguishing among cognitively normal, moderate cognitive impairment(MCI), i.e. prodromal Alzheimer's disease, and topics with Alzheimer's disease the use of gene expression and blood analytes.[15,17]

1. NGS sequencing in Alzheimer's disease

Next-technology sequencing (NGS) is an excessive throughput sequencing generation that gives ultra-excessive throughput, scalability, and speed. NGS has grown to be a standard device to find out questions highlighting DNA variations for the missing heritability, which may be located in plenty of genetically complex traits and genome resequencing. The first research on Alzheimer's disease speaks about their implications and limitations. Unique susceptibility alleles have been currently located by using NGS in APP, TREM2, and PLD3.

1.1. The sequencing method classified into two types:-

I. Ion Torrent - This technology converts nucleotide collection into virtual statistics on a semiconductor chip.[18] In DNA synthesis, a hydrogen ion is launched resulting accurate nucleotide integration throughout from its complementary base in a developing DNA chain.

II. Illumina sequencing - Also called "bridge amplification", on this DNA molecules (approximately 500 bp) with adapters ligated on every stop are used as substrates for repeated amplification synthesis reactions on a strong assist incorporating oligonucleotide sequences complementary to a ligated adapter. Creating clonal "clusters", including approximately a thousand copies of every oligonucleotide fragment, wherein DNA is subjected to repeated amplification. Different types of Illumina sequencing machines provide varying levels of throughput, which are MiniSeq, MiSeq, NextSeq, NovaSeq and HiSeq models.[19] Improvements in NGS permit for whole-genome or exome sequencing and comparisons of genomic records among people. GWAS of sufferers with SAD (who usually enjoy late-level onset) and healthful people have discovered that there is multiple single nucleotide polymorphisms (SNPs) which are related to SAD.[20,21]

2. Gene influenced Alzheimer's disease

It showed that positive genes function within the improvement of Early-onset Alzheimer disease (EOAD) or Late-onset Alzheimer's disease (LOAD). EOAD, also called Familial Alzheimer's disease was analyzed using the advancement of Alzheimer's disease earlier than the age of 65.[22] LOAD, also called Sporadic Alzheimer's disease, and analyzed the improving of Alzheimer's disease after the age of 65. EOAD susceptibility happens from having the genetic predisposition to predominantly produce the extra aggregation susceptible Aβ1-42 species rather than the Aβ1-40 species. The genes in this class are APP, PSEN1 and PSEN2. PSEN1 and PSEN2 encode the presenilin, which's the catalytic element of the complicated γ-secretase.[23] Mutations in PSEN1 and PSEN2 encourage the γ-secretase to offer a higher proportion of the Aβ1-42, which results in the formation of Aβ aggregates.[24] ApoE is a gene encoding the apolipoprotein E (ApoE), which impacts LOAD. There are three principal ApoE isoforms, ApoE2, ApoE3 and ApoE4, differentiated through amino acid substitutions at positions 112 and 158.[25] ApoE2 is determined to reduce Alzheimer sickness threat, and ApoE4 is determined to develop Alzheimer sickness threat.[26] The pathological consequences of apoE4 are because of lack of shielding characteristic or because of the benefit of poisonous characteristic is mentioned here. It is possible that each mechanism coexist, with sure materials of the apoE4 molecule or its downstream signaling mediating a poisonous effect, while others are related to a lack of shielding characteristic as shown in Fig. 2.



Fig. 2. ApoE4, a therapeutic target in Alzheimer's disease.

3. GWAS (Genome-wide association study)

Alzheimer's disease studies have mainly centered on early-onset familial instances pushed through mutations on APP or PSEN. Although they only contain approximately 5% of Alzheimer's disease

instances, the motive of pathology seems to be quite straightforward, as mutations in the genes are broadly characterized to bring about each will growth in well-known Aβ production or will growth inside the ratio of toxic Aβ species, eventually take place in neurodegeneration.[27] In GWAS, researchers try to become aware of SNPs related to Alzheimer's disease by statistically reading the frequency of variations within the genome of the disorder institution with regards to the manipulated institution. Interestingly, genetic hazard elements discovered by GWAS placed close to the genes concerned in diverse cell signaling pathways together with cholesterol metabolism, immune response, and endocytosis. Current research has suggested significant expression of ApoE in microglia.[28-31] ApoE synthesis is understood to grow at some point of harm and neurodegeneration.[29] Its central position in transporting lipids (which include cholesterol) throughout cells,[32] research has cautioned that ApoE regulates degrees of Aβ through physical interactions.[33,34] ApoE4 may also contribute to numerous practical abnormalities associated with Alzheimer's disease in more than one method through inflicting neurotoxicity, inducing synaptic dysfunction, and exacerbating neuroinflammation, mitochondrial dysfunction, and cerebrovascular defects.[35] An uncommon version of the TREM2 gene (R47H, rs75932628) is every other vital genetic threat component for Alzheimer's disease, mainly to a two-fold growth within the threat of its occurrence.[20,36] The genomic place and purposeful traits of those Alzheimer's disease-related genes are supplied in Table 1.

Table. 1. Genes which increase the risks of Alzheimer's disease.

Genes	Functions
CASS4	Influence the expression of APP and tau
MEF2C	Immune response and inflammation
NME8	Role in lowering brain in neurodegeneration
INPP5D	Lipid metabolism, homeostasis and endocytosis, INPP5D products participate in AD.
PTK2B	Act as an early marker

4. Potential Receptors highlighted during Alzheimer's disease research

4.1. Acetylcholine (ACh) receptors

ACh receptors are the maximum critical goal proteins that mainly bind to ACh neurotransmitters. These receptors are divided into nicotinic Ach receptors (nAChRs) and muscarinic receptors (MRs). Skeletal neuromuscular junctions and autonomic ganglia acknowledged through nAChRs while MRs are present inside the mind and parasympathetic effector organs and are associated with cognition in Alzheimer's disease.[37] M1/G-protein coupling substantially reduced with the development of Alzheimer's disease characterized by Tsang. However the density of M1 receptors has now no longer reduced.[38]

4.2. Adrenergic receptors

These receptors are metabotropic GPCRs (G-protein-coupled receptors), divided into predominant groups, α and β. The behavioural statement stated structural adjustments in adrenergic receptors with the presence or absence of aggressive behavior in Alzheimer's disease patients.[39]

4.3. Dopamine receptors

These receptors exhibit essential roles in various human functions, including cognition and learning.[40] These receptors are divided into two different classes, D1- and D2-like receptors, having five subtypes. D1-type receptors include D1 and D5 receptors, whereas D2-type receptors include D2, D3 and D4 receptors.[41] Stimulating the protein signalling cascade of cAMP/PKA and CREB modulation in synaptic plasticity and cognition by D1- and D2-type receptors.[42]

4.4. N-Methyl-D-aspartate (NMDA) receptors

These receptors are expressed in the cerebral cortex, hippocampus, nucleus accumbens and striatum.[43] Amyloid plaques are a consequence of NMDA receptor modulation; it induces neuronal loss.

NMDA receptors activated by amyloid plaques result in higher calcium influx into neurons, ERK1/2 activation and mediation of respective downstream enzymes.[44] The pathways of NMDA have a potential role in the pathogenesis of cognitive dysfunctions. However, uncontrolled NMDAR activity causes excitotoxicity and promotes cell loss of life, underlying a capability mechanism of neurodegeneration that took place in Alzheimer's disease as shown in Fig. 3.



Fig. 3. Role of receptors in Alzheimer's disease.

4.5. Acetyl cholinesterase (AChE) as a drug target

AChE is a type of hydrolase. It exhibits the functions of cholinergic neurotransmission in the autonomic and somatic nervous systems.[45]

5. Receptors used to treat AD

5.1. Acetyl cholinesterase (AChE) based inhibitors

Neuromuscular troubles are treated by AChE inhibitors. It is also considered as a first-generation drug for the treatment of Alzheimer's disease. There are four inhibitors that are probably normally used to decorate cognition are donepezil, galantamine, rivastigmine and tacrine.[46] Recently discovered that derivatives of Hup A, with aromatic rings, show off ability healing outcomes for Alzheimer's disease symptoms.[47]

5.2. β-secretase (BACE) as a therapeutic target

BACE1 inhibitors are arranged for the treatment of Alzheimer's disease. In a mouse study, Aβ manufacturing decreased in APP transgenic and ordinary mice following KMI-429 therapy, as confirmed through Asai.[48] The major effects of GRL-8234 on cerebrospinal fluid (CSF) and Aβ manufacturing is studied on transgenic mice through Chang.[49]

5.3. GSK-3 inhibitors



Fig. 4. Schematic illustration of the numerous mechanisms related to Alzheimer's Disease therapy.

Glycogen synthase kinase three (GSK-three) may also have high-quality healing outcomes on sufferers with Alzheimer's disease. It investigated that the compound SB216763-a (a GSK-three inhibitor) was characterized for ability use within the remedy of Alzheimer's disease. It reduced phospho-glycogen synthase by 39% and increased glycogen by 44%, demonstrating its potent inhibition of receptor activity.[50] It is tough to research the receptor-based mechanistic signaling pathways and the interactions of neurotransmitters with tablets through experimentation. So, computational modelling methods are taken into consideration as essential for focusing on and investigating neurodegeneration disorders. A variety of natural compounds

from specific origins became defined to be appropriate to save you and attenuate numerous pathologies, together with neurological diseases, which includes Alzheimer's disease. Since numerous reasons are associated with this disease, the preventive homes of the natural compounds may be related to numerous mechanisms as shown in Fig. 4.

6. Computational modelling of Alzheimer's disease

Computational models of Alzheimer's disease were designed on the basis of amyloid plaques, NFTs and hippocampus functions.

6.1. Plaque-based computational modeling:

Amyloid plaque formation is considered as a biochemical concept to format models. Processing and downstream intracellular interactions of calcium and Aβ have been placed in the Alzheimer's disease mind through Amyloid precursor protein (APP).[51] A computational model is built to account for established tendencies of Alzheimer's disease, which encompass its irreversibility, acute to persistent pathology and inherent random capabilities of sporadic Alzheimer's disease.

6.2. Neurocomputational model

Alzheimer's disease has reported changes in hippocampal functionality and behavioural performance by Computational exploration.[52] Simulated gaining knowledge of happening through an interplay among the hippocampal area and basal ganglia is diagnosed by Moustafa.[53] The practical affiliation among cortisol and the hippocampus in elderly people and sufferers with Alzheimer's disease is investigated by McAuley et al.[54]

6.3. Immunity-based modeling

The passive and active immunization effects against Aβ, plaques, phosphorylated-tau and tangles are investigated by Proctor.[55] The quick and mild staged inflammation and mutation results at the ApoE allele, this reason became investigated for the computational version.

6.4. Biomarkers of Alzheimer's disease

A biomarker is a parameter of physiological, biochemical or anatomical domains. It indicates normal biological and pathological processes or reactions to a therapeutic intervention. The crucial elements of Alzheimer's disease assist within the analysis of neurodegeneration.

6.5. Neurological biomarkers

Neuronal death occurs due to loss of neuronal synapses; it results in structural and functional changes in brain regions associated with memory, including frontal, temporal and parietal lobes. The chance of growing neurodegenerative illnesses because of the disruption of interconnected signaling pathways throughout more than one neurological area.[56] Highly precise and sensitive blood biomarkers, the usage of less-invasive techniques to detect Alzheimer's disease, are derived from the findings of peripheric tau based oligomers and amyloid variants present in human plasma and platelets. Successful researches on blood tau biomarkers results in a cognitive decline and also with neuroimaging determinations of mind atrophy as shown in figure 5.



Fig.5. Biomarkers in Alzheimer's disease neurobiology.

7.2. Glucose metabolism and oxidative free radicals as biomarkers

Biomarkers for neurodegenerative illnesses consist of glucose metabolism, oxidative loose radical harm to mitochondrial DNA, neuroreceptors and neurotransmitter useful activity.[57]

7.3. Blood-based biomarkers

Blood-based biomarkers also are used for Alzheimer's disease treatment.[58] The maximum outstanding problem is the presence of a multiple of dynamic ranges of proteins within the blood.[59] The blood-mind barrier is interrupted in aging sufferers with Alzheimer's disease. This effect in more desirable permeability is considered the primary indicator of cognitive impairment in Alzheimer's disease.

7.4. BACE1 and amyloid plaque-based biomarkers

BACE1 (beta-site amyloid precursor protein cleaving enzyme 1) activity may contribute to the amyloidogenic process in Alzheimer's disease.[60] It is taken into consideration to be a biomarker for tracking amyloidogenic APP metabolism within the CNS. Amyloid angiopathy is also considered a marker for Alzheimer's disease, because it involves the accumulation of amyloid protein within the cerebral blood vessels of sufferers with Alzheimer's disease.[61] AD biomarkers at initial exploratory stages, and biomarkers which are presently being examined in medical research are provided in Table 2.

Table 2. Biomarkers based on clinical research

Alzheimer's disease Biomarkers	Clinical research
Neurological	No
Glucose metabolism	Yes
Blood-based	Preclinical
Amyloid plaque-based	Yes

8. Role of Molecular simulations in the treatment of Alzheimer's disease

Alzheimer's disease is the maximum deadly neurodegenerative disease analyzed using aggregation and deposition of Amyloid-beta (Aβ) fibrils within the mind of patients. The main additives of AD-related amyloid plaques are Aβ1–40 peptides, however, the greater poisonous Aβ1–42 species,[62] recognized by way of means of different amino acids and generated through a sequential cleavage of the amyloid precursor protein (APP) by way of means of β and γ-secretases.[63]

The amyloid hypothesis is based at the concept that a mutation on an amyloid precursor protein (APP) induces the aggregation of Aβ peptides, whose deposition into senile plaques is observed by the formation of neurofibrillary tangles and neuronal cell death.[64] But it is still not clear if the fibril formation event is the cause or a secondary effect of the disease.[65] Within this context, the computational techniques represent a powerful tool able to becoming a member of macroscopic experimental findings to nanoscale molecular events.

Targeting Aβ aggregation gives a widespread challenge. Using the concept of docking and MD research may lead into the improvement of compounds that could inhibit Aβ aggregation and consequently function capacity healing marketers towards Alzheimer's disease.

8.1. Amyloid hypothesis

The lifestyles of the strong fibrillar deposits in the organs of patients affected by protein deposition sickness led to the low cost postulate that amyloid fibrils were the main cause for the diseases. Within this framework, the ABOs were considered as intermediate states to the technology of amyloid plaques answerable for Alzheimer's disease.

8.2. Docking

Molecular docking derives its ability from the idea that a small molecule can accompany a predefined binding web page of a few macromolecules. Docking calls for intelligent systems of a receptor molecule, generally an enzyme or receptor protein to which the ligand will bind may solve drug clues for AD.

8.3. Bioinformatics application in Alzheimer's disease

Alzheimer sickness is one of the most excessive kinds of dementia that reasons problems with reminiscence, thinking, and behavior. Biotechnology and bioinformatics are these days concerned in the hooked up order of advanced techniques of evaluation and treatment, which include molecular medicine, personalized medicine, gene identification and manipulation, further to neural engineering. NGS is one of the most influential approaches for reading genetic illnesses and gene mutations. It also includes genome-wide affiliation research and the function of microbiome detection in Alzheimer's disease.

8.4. Drug targets

There is a futuristic need to find out remedial alternatives for Alzheimer because of the disorder prevalence upward push in the approaching years. *In silico* drug repurposing tackles speed, value and protection problems in drug research. Current approach of gene signature assessment tools proposes that PKC, HDAC, ARG and GSK3 inhibitors might also be needed to oppose Alzheimer-induced gene expression patterns, therefore tackling the sickness phenotype. However, other drug houses want to be evaluated as well, regarding pharmacokinetics, pharmacodynamics, blood mind barrier permeability and toxicity. These are non-factors of drug development in Alzheimer, especially at the same time as the disease complexity imposes a polypharmacological approach as established in unique neurodegenerative diseases.[66]

CONCLUSION

Alzheimer's disease is a slow neurodegenerative sickness, while patho-physiological irregularities bring about obvious symptoms and signs together with excessive memory loss. GWAS and genomic research has shed new light on the mechanisms underlying the onset and development of Alzheimer's disease. Epigenetic adjustments can remodel our genome (without genetic threat elements) to be greater susceptible to Alzheimer's disease. The environmental factors influence the epigenetic regulators, marked as an example for the Alzheimer's disease improvement. Drug based computational modelling and simulation futuristic approaches aid in understanding and selection of chemical substances can be synthesized to deal with Alzheimer's disease.

ACKNOWLEDGEMENT

We sincerely thanks Head of Dept. of Tech. Bio-sciences Digianalix for providing us facilities for conducting research.

Conflict of Interest

The authors declare no conflict of interest.

Author's Contribution

Sadaf Naaz, Sweety Guria Rani, Purbasha Pati, Kumari Surekha Mahto, Shekhar Marandi, Rupa Verma, Neha Kumari, Pooja Kumari, Priyangulta Beck, Nawed Anjum did intensive research on various topics in this review article; Sadaf Naaz, Sweety Guria Rani, Kumari Surekha Mahto contributed in writing the manuscript; Scientist Mukesh Nitin designed and supervised the present review article and assisted in writing the paper.

Source of Funding: None

Ethical Approval: Not Applicable

REFERENCES

1. Blennow K, De Leon M.J., Zetterberg H, Alzheimer's disease. The Lancet. (2006) 368(9533):387–403, https://doi.org/10.1016/S0140-6736(06)69113-7.
2. Alzheimer's Association, Alzheimer's disease facts and figures, Alzheimers Dement. (2017) 13(4):325–73, https://doi.org/10.1016/j.jalz.2017.02.001.

3. Dosunmu R, Wu. J, Basha M.R, N.H. Zawia, Environmental and dietary risk factors in Alzheimer's disease, Expert Review of Neurotherapeutics. (2007) 7(7):887–900,https://doi.org/10.1586/14737175.7.7.887.
4. Wenk G.L., Neuropathologic changes in Alzheimer's disease, Clin J. Psychiatry. (2003) 64 Suppl 9. S7–S10, https://doi.org/10.3892/mmr.2018.9044.
5. Turner P.R., O'Connor K., Tate W.P.A., braham W.C., Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory, ProgNeurobiol. (2003), 70:1–32, https://doi.org/10.1016/S0301-0082(03)00089-3
6. Stoccoro A, Coppede F, Role of epigenetics in Alzheimer's disease pathogenesis, Neurodegenerative Disease Management. (2018), 8, 181–193, https://doi.org/10.2217/nmt-2018-0004
7. Dunckley T. , Beach T.G. , Ramsey K.E. , Grover A. , Mastroeni D. , Walker D.G et al., Gene expression correlates of neurofibrillary tangles in Alzheimer's disease, Neurobiology Aging, (2006), 27, 1359–1371.https://doi.org/10.1016/j.neurobiolaging.2005.08.013
8. Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H et al., The nhgrigwas catalog, a curated resource of snp-trait associations, Nucleic Acids Res. 42 (D1) (2014), pp. D1001-D1006, https://doi.org/10.1161/CIRCGEN.119.002775.
9. Visscher P.M, Wray N.R, Zhang Q, Sklar P, McCarthy M.I, Brown M.A et al., 10 years of gwas discovery: biology, function, and translation, Am J Hum Genet. 101 (1) (2017), pp. 5-22, https://doi.org/10.1016/j.ajhg.2017.06.005.
10. Lambert J.C, Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease, Nat. Genet. (2013), 45:1452–1458, https://doi.org/10.1038/ng.2802.
11. Van Cauwenberghe C, Van Broeckhoven C, Sleegers K, The genetic landscape of Alzheimer disease: clinical implications and perspectives, Genet. Med. (2016), 18:421–430, https://doi.org/10.1038/gim.2015.117.
12. Escott-Price V, Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease, PLoS One. (2014), 9:e94661, https://doi.org/10.1371/journal.pone.0094661.
13. Mapstone M, Plasma phospholipids identify antecedent memory impairment in older adults, Nat. Med. (2014), 20:415–418, https://doi.org/10.1038/nm.3466.
14. Long J, Pan G, Ifeachor E, Belshaw R, Li X, Discovery of Novel Biomarkers for Alzheimer's Disease from Blood, Dis. Markers. (2016), 2016:4250480, https://doi.org/10.1155/2016/4250480.
15. Fehlbaum-Beurdeley P, Toward an Alzheimer's disease diagnosis via high-resolution blood gene expression, Alzheimers Dement. (2010), 6:25–38, https://doi.org/10.1016/j.jalz.2009.07.001.
16. Lunnon K, A blood gene expression marker of early Alzheimer's disease, J. Alzheimers Dis. (2013), 33:737–753, https://doi.org/10.3233/jad-2012-121363.
17. O'Bryant S.E, A serum protein-based algorithm for the detection of Alzheimer disease, Arch. Neurol. (2010), 67:1077–1081, https://doi.org/10.1001/archneurol.2010.215
18. Rothberg J.M, Hinz W, Rearick T.M, Schultz J, Mileski W, Davey M et al., An integrated semiconductor device enabling non-optical genome sequencing, Nature. (2011), 475(7356):348–352, https://doi.org/10.1038/nature10242.
19. Chen L, Liu P, Evans T.C, Ettwiller L.M, DNA damage is a major cause of sequencing errors, directly confounding variant identification, bioRxiv. (2016), https://doi.org/10.1101/070334.
20. Wolfe M.S, γ-Secretase inhibitors and modulators for Alzheimer's disease, J. Neurochem. (2012), 120(Suppl. 1):89–98, https://doi.org/10.1111/j.1471-4159.2011.07501.x.
21. Lambert J.C, Ibrahim-Verbaas C.A, Harold D, Naj A.C, Sims R, Bellenguez C et al., Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease, Nat. Genet. (2013), 45:1452–1458, https://doi.org/10.1038/ng.2802.
22. Mendez M.F, Early-Onset Alzheimer Disease, Neurologic Clinics. (2017), 35,

263-281, https://doi.org/10.1016/j.ncl.2017.01.005.
23. Wolfe M.S, Unlocking Truths of Gamma-Secretase in Alzheimer's Disease: What Is the Translational Potential? Future Neurology. (2014), 9, 419-429, https://doi.org/10.2217/fnl.14.35.
24. Borchelt, Thinakaran, Eckman, Davenport, F., Ratovitsky et al., Familial Alzheimer's Disease-Linked Presenilin 1 Variants Elevate Aβ1-42/1-40 Ratio in Vitro and in Vivo, Neuron. (1996), 17, 1005-1013, https://doi.org/10.1016/S0896-6273(00)80230-5.
25. Wu L, Zhao L, ApoE2 and Alzheimer's Disease: Time to Take a Closer Look, Neural Regeneration Research. (2016), 11, 412-413, http://dx.doi.org/10.4103/1673-5374.179044.
26. Liu C.C, Liu C.C, Kanekiyo T, Xu H, Bu G, Apolipoprotein E and Alzheimer Disease: Risk, Mechanisms and Therapy, Nature Reviews Neurology. (2013), 9, 106-118, https://doi.org/10.1038/nrneurol.2012.263.
27. Hardy J, Selkoe D.J, The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics, Science. (2002), 297:353–356, https://doi.org/10.1126/science.1072994.
28. Pimenova A.A, Marcora E, Goate A.M, A Tale of Two Genes: Microglial Apoe and Trem2. Immunity. (2017), 47:398–400, https://doi.org/10.1016/j.immuni.2017.08.015.
29. Ignatius M.J, Gebicke-Härter P.J, Skene J.H, Schilling J.W, Weisgraber K.H, Mahley R.W et al., Expression of apolipoprotein E during nerve degeneration and regeneration. Proc. Natl. Acad. Sci. USA. (1986), 83:1125–1129, https://doi.org/10.1073/pnas.83.4.1125.
30. Boyles J.K, Pitas R.E, Wilson E, Mahley R.W, Taylor J.M, Apolipoprotein E is associated with astrocytic glia of the central nervous system and with non myelinating glia of the peripheral nervous system. J. Clin. Investig. (1985), 76:1501–1513, https://doi.org/10.1172/JCI112130.
31. Pitas R.E, Boyles J.K, Lee S.H, Foss D, Mahley R.W, Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim. Biophys. Acta. (1987), 917:148–161, https://doi.org/10.1016/0005-2760(87).
32. Mahley R.W, Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science. (1988), 240:622–630, https://doi.org/10.1126/science.3283935.
33. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K, Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. (1991), 541:163–166, https://doi.org/10.1016/0006-8993(91)91092-F.
34. Liu C.C, Kanekiyo T, Xu H, Bu G, Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat. Rev. Neurol. (2013), 9:106–118. https://doi.org/10.1038/nrneurol.2012.263.
35. Yamazaki Y, Painter M.M, Bu G, Kanekiyo T, Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence. CNS Drugs. (2016), 30:773–789, https://doi.org/10.1007/s40263-016-0361-4.
36. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, P. Jonsson V, Bjornsson S et al., Variant of TREM2 associated with the risk of Alzheimer's disease. N. Engl. J. Med. (2013), 368:107–116, https://doi.org/10.1056/NEJMoa1211103.
37. Alzheimer's Disease Facts and Figures, (2011) http://www.alz.org/downloads/Facts_Figures_2011.pdf.
38. Hardy J.A, Higgins G.A, Alzheimer's Disease: The Amyloid Cascade Hypothesis. Science (1992), 256, 184–185, https://doi.org/10.1126/science.1566067.
39. R.C. Alzheimer's. Disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis. (2012), 2012:1–11, https://doi.org/10.1155/2012/369808.
40. Aguzzi A, O'Connor T., Protein aggregation diseases: pathogenicity and therapeutic perspectives, Nat Rev Drug Discov. (2010), 9:237–248, https://doi.org/10.1038/nrd3050.
41. Bhatia A, Lenchner JR, Saadabadi A. Biochemistry, Dopamine Receptors. [Updated 2021 Jul 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538242/
42. Schütz A.K, Vagt T, Huber M, Atomic-resolution three-dimensional structure of

amyloid β fibrils bearing the osaka mutation, AngewChemie Int Ed. (2015), 54:331–335, https://doi.org/10.1002/anie.201408598.
43. Chiti F, Dobson C.M, Protein misfolding, functional amyloid, and human disease, Annu Rev Biochem. (2006), 75:333–366, https://doi.org/10.1146/annurev.biochem.75.101304.123901.
44. Chiti F, Dobson C.M.C, Amyloid formation by globular proteins under native conditions, Nat Chem Biol. (2008), 5:15–22, https://doi.org/10.1038/nchembio.131.
45. Tayeb H.O, Yang H.D, Price B.H, Tarazi F.I, Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors, Pharmacol. Ther. (2012), 134, 8–25, https://doi.org/10.1016/j.pharmthera.2011.12.002.
46. Frackowiak J, Zoltowaka A, Wiśniewski H.M, Non-fibrillar β-amyloid protein is associated with smooth muscle cells of vessel walls in Alzheimer disease, J. Neuropathol Exp Neurol, (1994), 53:637–645, https://doi.org/10.1097/00005072-199411000-00011.
47. Noguchi A, Matsumura S, Dezawa M, Isolation and characterization of patient-derived, toxic, high mass amyloid β-protein (Aβ) assembly from Alzheimer disease brains, J. Biol Chem. (2009), 284:32895–32905, http://dx.doi.org/10.1074/jbc.M109.000208.
48. Mc Donald J.M, Savva G.M, Brayne C, The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia. Brain. (2010), 133:1328–1341, https://doi.org/10.1093/brain/awq065.
49. Pham E, Crews L, Ubhi K, Hansen L, Adame A, Cartier A et al., Progressive accumulation of amyloid-β oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins, Febs J. (2010), 277:3051–3067, https://doi.org/10.1111/j.1742-4658.2010.07719.x.
50. Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein W.L et al., Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1, Eur J. Neurosci. (2006), 23:251–260, https://doi.org/10.1111/j.1460-9568.2005.04551.x.
51. Esparza T.J, Zhao H, Cirrito J.R, Cairns N.J, Bateman R.J, Holtzman D.M et al., Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls, Ann Neurol. (2013), 73:104–119, https://doi.org/10.1002/ana.23748.
52. Serra-Batiste M, Tolchard J, Giusti F, Stabilization of a membrane-associated amyloid-β oligomer for its validation in Alzheimer's disease, Front MolBiosci. (2018), 5. https://doi.org/10.3389/fmolb.2018.00038.
53. Haass C, Selkoe D.J, Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide, Nat Rev Mol Cell Biol. (2007), 8:101–112, doi: 10.1038/nrm2101, https://doi.org/10.1038/nrm2101.
54. Härd T, Lendel C, Inhibition of amyloid formation, J Mol Biol. (2012), 421:441–465, https://doi.org/10.1016/j.jmb.2011.12.062.
55. Williams T.L, Johnson B.R.G, Urbanc B et al., Aβ42 oligomers, but not fibrils, simultaneously bind to and cause damage to ganglioside-containing lipid membranes, Biochem J. (2011), 439:67–77, http://dx.doi.org/10.1042/BJ20110750.
56. Cecchi C, Stefani M, The amyloid-cell membrane system. The interplay between the biophysical features of oligomers/fibrils and cell membrane defines amyloid toxicity, Biophys Chem. (2013), 182:30–43, https://doi.org/10.1016/j.bpc.2013.06.003.
57. Winklhofer K.F, Tatzelt J, Haass C, The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases, Embo J. (2008), 27:336–349, http://dx.doi.org/10.1038/sj.emboj.7601930.
58. Treusch S, Cyr D.M, Lindquist S, Amyloid deposits: protection against toxic protein species? Cell Cycle. (2009), 8:1668–1674, https://doi.org/10.4161/cc.8.11.8503.
59. Benilova I, Karran E, De Strooper B, The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes, Nat Neurosci. (2012), 15:349–357, doi: 10.1038/nn.3028, https://doi.org/10.1038/nn.3028.
60. Reed M.N, Hofmeister J.J, Jungbauer L, Cognitive effects of cell-derived and synthetically derived Aβ oligomers, Neurobiol Aging. (2011), 32:1784–1794,

https://doi.org/10.1016/j.neurobiolaging.2009.11.007
61. Kitchen D.B, Decornez H, Furr J. R, Bajorath J, Docking and scoring in virtual screening for drug discovery: Methods and applications, Nat. Rev. Drug Discovery. (2004), 3, 935–949, https://doi.org/10.1038/nrd1549.
62. Leach A.R, Schoichet B.K, Peishoff C.E, Prediction of Protein-Ligand Interactions. Docking and Scoring: Successes and Gaps, J. Med. Chem. (2006), 49, 5851–5855, https://doi.org/10.1021/jm060999m.
63. Moitessier N, Englebienne P, Lee D, Lawandi J, Corbeil C.R, Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go, Br. J. Pharmacol. (2008), 153, S7–S26, https://doi.org/10.1038/sj.bjp.0707515.
64. Lindorff-Larsen K, Maragakis P, Piana S, Systematic validation of protein force fields against experimental data, PLoS One. (2012), 7:e32131, https://doi.org/10.1371/journal.pone.0032131.
65. Beauchamp K.A, Lin Y.S, Das R, Pande V.S, Are protein force fields getting better? A systematic benchmark on 524 diverse NMR measurements, J Chem Theory Comput. (2012), 8:1409–1414, https://doi.org/10.1021/ct2007814.
66. M.C. Boll, L. Bayliss, S. Vargas-Cañas, J. Burgos, S. Montes, M. Alcaraz-Zubeldia, et al., Clinical and biological changes under treatment with lithium carbonate and valproic acid in sporadic amyotrophic lateral sclerosis, J Neurol Sci (2014), 340 (1–2): 103 – 8 . https://doi.org/10.1016/j.jns.2014.03.005.

How to cite this article: Sadaf Naaz, Sweety Guria Rani, Purbasha Pati et.al. Current incorporation and impact of computational biology in Alzheimer's disease. *Int J Health Sci Res.* 2022; 12(3): 346-357. DOI: *https://doi.org/10.52403/ijhsr.20220345*

******